Amgen Inc. and HUTCHMED (China) Limited: A Detailed Gross Profit Analysis

A Tale of Two Companies: Amgen Inc. vs. HUTCHMED (China) Limited

In the world of biotechnology, Amgen Inc. and HUTCHMED (China) Limited stand as intriguing contrasts. Over the past decade, Amgen has consistently demonstrated robust financial health, with its gross profit growing by approximately 26% from 2014 to 2023. In 2023 alone, Amgen's gross profit reached nearly $20 billion, showcasing its dominance in the industry.

Conversely, HUTCHMED (China) Limited, while smaller in scale, has shown remarkable growth. From a modest gross profit of around $20 million in 2014, it surged to over $450 million by 2023, marking an impressive increase of over 2,000%. This growth trajectory highlights HUTCHMED's potential in the rapidly expanding Chinese biotech market.

This analysis underscores the diverse strategies and market dynamics that shape the biotech landscape, offering valuable insights for investors and industry enthusiasts alike.